This study is exploring the safety and effectiveness of a new treatment plan using ublituximab for people with relapsing multiple sclerosis (RMS). RMS is a type of multiple sclerosis where symptoms can flare up and then improve. Ublituximab is a medicine designed to help control RMS symptoms. The study has three parts:
- Part A: Everyone gets the treatment and knows what it is.
- Part B: Some people get the treatment, and some get a placebo (a fake treatment), but no one knows which one they receive.
- Part C: Everyone gets the treatment, focusing on those who didn't do well on another similar treatment.
To join, you must have RMS and meet specific health criteria. This study includes rules about past treatments and current health conditions. It lasts for some time, requiring visits to the study site. There might be risks, like side effects from the medicine.
- This study is divided into three parts with different approaches.
- Participants must meet specific health requirements.
- Potential side effects from the treatment need to be considered.
How understandable was the trial content above?
Hard to understand
Easy to understand